CU Logo University of Colorado Anschutz Medical Campus
Back to Results

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma

Primary Objective

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Is This Study For You?

Let's Get Started!

Description

You are being asked to be in this research study because you have previously had surgery to remove your cancer and are now considered clinically disease-free. This study plans to learn more about whether or not the combination of pembrolizumab and mRNA-4157 (a personalized cancer vaccine) works better than just pembrolizumab to prevent your type of cancer from coming back.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Locations

University of Colorado Hospital

Principal Investigator
Photograph of Theresa Medina

Theresa Medina

Study ID

Protocol Number: 19-0642

More information available at ClinicalTrials.gov: NCT03897881

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers